Italia markets open in 6 hours 13 minutes

FibroGen, Inc. (0IL8.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
23,64+1,31 (+5,87%)
Alla chiusura: 04:17PM GMT
Schermo intero
Chiusura precedente22,33
Aperto0,00
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno0,00 - 0,00
Intervallo di 52 settimane
Volume75
Media VolumeN/D
Capitalizzazione16,706M
Beta (5 anni mensile)0,72
Rapporto PE (ttm)N/D
EPS (ttm)-3,04
Prossima data utili27 feb 2023 - 03 mar 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    FibroGen to Present at SVB Securities Global Biopharma Conference

    SAN FRANCISCO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Thursday, February 16 at 3:40 PM Eastern Time. The live audio webcast of the event will be available to investors and other interested parties on the “Events & Presentations” section of the FibroGen Investor webpage at www.fibrogen.com. A replay will be availa

  • GlobeNewswire

    FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference

    SAN FRANCISCO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of America 2022 Biotech SMID Cap Virtual Conference on December 8, at 1:05 PM Eastern Time. A live audio webcast of the event will be available on the “Events & Presentations” section of the FibroGen Investors webpage at www.fibrogen.com. The replay will be available for approximately 30 days. About FibroGen

  • GlobeNewswire

    FibroGen Reports Third Quarter 2022 Financial Results

    Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024Completed enrollment of MATTERHORN Phase 3 study of roxadustat in patients with anemia of myelodysplastic syndromes with topline data expected 1H 2023Strong roxadustat volume growth in China of over 80% vs 3Q 2021Announced non-dilutive royalty monetization transaction with NovaQuest for $50 million of capital secured by 22.5% of roxadustat royalty revenue in t